BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35414481)

  • 1. Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals.
    Levink IJM; Klatte DCF; Hanna-Sawires RG; Vreeker GCM; Ibrahim IS; van der Burgt YEM; Overbeek KA; Koopmann BDM; Cahen DL; Fuhler GM; Wuhrer M; Bonsing BA; Tollenaar RAEM; Vleggaar FP; Vasen HFA; van Leerdam ME; Bruno MJ; Mesker WE
    Pancreatology; 2022 May; 22(4):497-506. PubMed ID: 35414481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.
    Vasen H; Ibrahim I; Ponce CG; Slater EP; Matthäi E; Carrato A; Earl J; Robbers K; van Mil AM; Potjer T; Bonsing BA; de Vos Tot Nederveen Cappel WH; Bergman W; Wasser M; Morreau H; Klöppel G; Schicker C; Steinkamp M; Figiel J; Esposito I; Mocci E; Vazquez-Sequeiros E; Sanjuanbenito A; Muñoz-Beltran M; Montans J; Langer P; Fendrich V; Bartsch DK
    J Clin Oncol; 2016 Jun; 34(17):2010-9. PubMed ID: 27114589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum N-Glycome analysis reveals pancreatic cancer disease signatures.
    Vreeker GCM; Hanna-Sawires RG; Mohammed Y; Bladergroen MR; Nicolardi S; Dotz V; Nouta J; Bonsing BA; Mesker WE; van der Burgt YEM; Wuhrer M; Tollenaar RAEM
    Cancer Med; 2020 Nov; 9(22):8519-8529. PubMed ID: 32898301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging Mass Spectrometry and Lectin Analysis of N-Linked Glycans in Carbohydrate Antigen-Defined Pancreatic Cancer Tissues.
    McDowell CT; Klamer Z; Hall J; West CA; Wisniewski L; Powers TW; Angel PM; Mehta AS; Lewin DN; Haab BB; Drake RR
    Mol Cell Proteomics; 2021; 20():100012. PubMed ID: 33581409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multivariate data analysis for the detection of human alpha-acid glycoprotein aberrant glycosylation in pancreatic ductal adenocarcinoma.
    Mancera-Arteu M; Giménez E; Balmaña M; Barrabés S; Albiol-Quer M; Fort E; Peracaula R; Sanz-Nebot V
    J Proteomics; 2019 Mar; 195():76-87. PubMed ID: 30641231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance Outcome and Genetic Findings in Individuals at High Risk of Pancreatic Cancer.
    Rosner G; Scapa E; Ziv T; Gluck N; Ben-Yehoyada M
    Clin Transl Gastroenterol; 2024 Feb; 15(2):e00668. PubMed ID: 38147532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PanGen-Fam: Spanish registry of hereditary pancreatic cancer.
    Mocci E; Guillen-Ponce C; Earl J; Marquez M; Solera J; Salazar-López MT; Calcedo-Arnáiz C; Vázquez-Sequeiros E; Montans J; Muñoz-Beltrán M; Vicente-Bártulos A; González-Gordaliza C; Sanjuanbenito A; Guerrero C; Mendía E; Lisa E; Lobo E; Martínez JC; Real FX; Malats N; Carrato A
    Eur J Cancer; 2015 Sep; 51(14):1911-7. PubMed ID: 26212471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased α1-3 fucosylation of α-1-acid glycoprotein (AGP) in pancreatic cancer.
    Balmaña M; Giménez E; Puerta A; Llop E; Figueras J; Fort E; Sanz-Nebot V; de Bolós C; Rizzi A; Barrabés S; de Frutos M; Peracaula R
    J Proteomics; 2016 Jan; 132():144-54. PubMed ID: 26563517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The benefit of pancreatic cancer surveillance in carriers of germline BRCA1/2 pathogenic variants.
    Laish I; Schechter M; Dancour A; Lieberman S; Levi Z; Goldberg Y; Kedar I; Hasnis E; Half E; Levi GR; Katz L; Vainer ED; Genzel D; Aharoni M; Chen-Shtoyerman R; Abu-Freha N; Raitses-Gurevich M; Golan T; Bernstein-Molho R; Ben Yehoyada M; Gluck N; Rosner G
    Cancer; 2024 Jan; 130(2):256-266. PubMed ID: 37861363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation in precursor lesions of pancreatic cancer among high-risk groups.
    Potjer TP; Schot I; Langer P; Heverhagen JT; Wasser MN; Slater EP; Klöppel G; Morreau HM; Bonsing BA; de Vos Tot Nederveen Cappel WH; Bargello M; Gress TM; Vasen HF; Bartsch DK; ;
    Clin Cancer Res; 2013 Jan; 19(2):442-9. PubMed ID: 23172884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Growth Rate of Pancreatic Ductal Adenocarcinoma in
    Ibrahim IS; Wasser MN; Wu Y; Inderson A; de Vos Tot Nederveen Cappel WH; Morreau H; Hes FJ; Veenendaal RA; Putter H; Feshtali S; van Mil AM; Gruis NA; Tollenaar RA; Bergman W; Bonsing BA; Vasen HFA
    Cancer Prev Res (Phila); 2018 Sep; 11(9):551-556. PubMed ID: 29991580
    [No Abstract]   [Full Text] [Related]  

  • 12. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening.
    Cremin C; Lee MK; Hong Q; Hoeschen C; Mackenzie A; Dixon K; McCullum M; Nuk J; Kalloger S; Karasinska J; Scudamore C; Kim PTW; Donnellan F; Lam ECS; Lim HJ; Neben CL; Stedden W; Zhou AY; Schaeffer DF; Sun S; Renouf DJ; Schrader KA
    Cancer Med; 2020 Jun; 9(11):4004-4013. PubMed ID: 32255556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term yield of pancreatic cancer surveillance in high-risk individuals.
    Overbeek KA; Levink IJM; Koopmann BDM; Harinck F; Konings ICAW; Ausems MGEM; Wagner A; Fockens P; van Eijck CH; Groot Koerkamp B; Busch ORC; Besselink MG; Bastiaansen BAJ; van Driel LMJW; Erler NS; Vleggaar FP; Poley JW; Cahen DL; van Hooft JE; Bruno MJ;
    Gut; 2022 Jun; 71(6):1152-1160. PubMed ID: 33820756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial Pancreatic Ductal Adenocarcinoma.
    Diaz KE; Lucas AL
    Am J Pathol; 2019 Jan; 189(1):36-43. PubMed ID: 30558720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EUS-based Pancreatic Cancer Surveillance in
    Katona BW; Long JM; Ahmad NA; Attalla S; Bradbury AR; Carpenter EL; Clark DF; Constantino G; Das KK; Domchek SM; Dudzik C; Ebrahimzadeh J; Ginsberg GG; Heiman J; Kochman ML; Maxwell KN; McKenna DB; Powers J; Shah PD; Wangensteen KJ; Rustgi AK
    Cancer Prev Res (Phila); 2021 Nov; 14(11):1033-1040. PubMed ID: 34341011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic Cancer Surveillance in Carriers of a Germline
    Klatte DCF; Boekestijn B; Wasser MNJM; Feshtali Shahbazi S; Ibrahim IS; Mieog JSD; Luelmo SAC; Morreau H; Potjer TP; Inderson A; Boonstra JJ; Dekker FW; Vasen HFA; van Hooft JE; Bonsing BA; van Leerdam ME
    J Clin Oncol; 2022 Oct; 40(28):3267-3277. PubMed ID: 35658523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Approaches to Pancreatic Cancer Screening.
    Chhoda A; Lu L; Clerkin BM; Risch H; Farrell JJ
    Am J Pathol; 2019 Jan; 189(1):22-35. PubMed ID: 30558719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
    Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
    Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated Systems Analysis of the Murine and Human Pancreatic Cancer Glycomes Reveals a Tumor-Promoting Role for ST6GAL1.
    Kurz E; Chen S; Vucic E; Baptiste G; Loomis C; Agrawal P; Hajdu C; Bar-Sagi D; Mahal LK
    Mol Cell Proteomics; 2021; 20():100160. PubMed ID: 34634466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits.
    Rodriguez E; Boelaars K; Brown K; Madunić K; van Ee T; Dijk F; Verheij J; Li RJE; Schetters STT; Meijer LL; Le Large TYS; Driehuis E; Clevers H; Bruijns SCM; O'Toole T; van Vliet SJ; Bijlsma MF; Wuhrer M; Kazemier G; Giovannetti E; Garcia-Vallejo JJ; van Kooyk Y
    Commun Biol; 2022 Jan; 5(1):41. PubMed ID: 35017635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.